Unknown

Dataset Information

Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma.


ABSTRACT: Clear cell sarcoma is an aggressive soft tissue sarcoma and highly resistant to conventional chemotherapy and radiation therapy. This devastating disease is defined by EWSR1-ATF1 fusion gene resulting from chromosomal translocation t(12;22)(q13;q12) and characterized by melanocytic differentiation. A marine-derived antineoplastic agent, trabectedin, inhibits the growth of myxoid liposarcoma and Ewing sarcoma by causing adipogenic differentiation and neural differentiation, respectively. In this study, we examined the antitumor effects and mechanism of action of trabectedin on human clear cell sarcoma cell lines. We showed that trabectedin decreased the cell proliferation of five clear cell sarcoma cell lines in a dose-dependent manner in vitro and reduced tumor growth of two mouse xenograf

SUBMITTER: Nakai T 

PROVIDER: S-EPMC5603837 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature